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Introduction
H
epatitis B virus (HBV) infects more than 350 
million people worldwide. It is a leading cause 
of  chronic  hepatitis,  cirrhosis,  and  hepatocellular 
carcinoma, and these sequels of chronic infection 
account for more than 1 million deaths annually (1). 
Immunization of infants against HBV has proven to 
be the most effective way to prevent infection (2).
Approximately 3% of Iranian people are chronic 
carriers.  However,  the  rate  is  different  among 
provinces  (3).  In  Kohgiloyeh  and  Boierahmad 
province the incidence rate was 15.3 per 100,000, 
* Correspondence:
Mitra Safari, M.Sc.
School of Nursing and Midwifery, Yasouj University of Medi-
cal Sciences, Yasouj, Iran.
Tel: +98 741 223 5141 
Fax: +98 741 222 3114 
E-mail: mitra_safari39@yahoo.com
Received:  18 Mar 2009                 Revised:  4 Dec 2009 
Accepted:  24 Dec 2009 
Hepat Mon 2010; 10 (1): 17-21
Background and Aims: The duration of the protection of hepatitis B vaccination for infants and the necessity of a booster 
dose administration is unknown. The aim of the present study was to evaluate the persistence of seroprotection after 
hepatitis B virus (HBV) vaccination in order to determine the necessity of a single booster dose in 5- to 7-year-old chil-
dren.
Methods: This clinical trial study was conducted from 2004 to 2005. The study population included all children aged 5 
to 7 years old in the Kohgiloyeh and Boyerahmad province who had been vaccinated starting at birth with hepatitis B 
vaccine. Among these children, 729 were selected via a multiple-stage sampling method. Parents gave their informed 
consent, and blood specimens (3 ml) were obtained from children. Hepatitis B surface antibody (HBsAb) and hepatitis B 
surface antigen (HBsAg) were determined by enzyme-linked immunosorbent assay (ELISA). Subjects with nonprotective 
titer levels (< 10 mIU/ml) received a booster does of the DNA recombinant vaccine. Four weeks after the administration 
of a booster dose, the antibody to HBsAg (anti-HBs) titer was measured. Data were analyzed using SPSS software, and 
analyses included chi-square, ANOVA, and independent-samples and paired-samples t-tests.
Results: 615 children (84.4%) had a protective antibody titer. The mean antibody titer was 230.5 ± 308.9 IU/ml, with 
a range of 10.6 to 1175 IU/ml. 15.6% of subjects had a nonprotective antibody titer, and the mean antibody titer was 
4.97 ± 3.5 IU/ml. All subjects were HBsAg negative. No statistically significant differences were found by sex or by urban 
versus rural area of residence. The seroprotection rates significantly decreased by as the age of the children increased. 
Following the booster dose, 78.1 % of the children had a protective titer, and the mean titer significantly increased from 
4.97 ± 3.5 at birth to 332.1 ± 402 IU/ml after the booster (P < 0.001). 
Conclusions: According to our results, the proper response of the immune system to a booster dose of HBV at 5 to 7 years 
of age reveals that immunologic memory is good after primary vaccination. Administration of booster dose does not ap-
pear to be necessary at these ages even though these children have a greater possibility of exposure to HBV in school 
age. 
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which is higher than the mean rate for the country 
as  a  whole  (12.4  in  100000)  (4).  The  National 
Committee of Expanded Program of Immunization 
has approved the addition of hepatitis B vaccine to 
the previous immunization program, which has been 
in effect since 1993. The program ensures that all 
newborns  receive  all  three  doses  of  recombinant 
hepatitis B vaccine shortly after birth, one month 
later, and then at 6 months age.
The  standard  HBV  antibody  (anti-HBV) 
vaccination elicits a protective antibody to hepatitis 
surface  antigen  (anti-HBs)  levels  in  most  people. 
However, the persistence of anti-HBs’s protective 
levels  after  vaccination  and  the  effective  duration 
of  immunologic  memory  is  not  well  understood 
(5).  The  measurement  of  post  vaccination  serum 
level of anti-HBs is the only simple test available to 
predict the waning of protection and help plan for 
the administration of a booster dose (6).
In unresponsive subjects a booster dose has been 
shown to be efficient, although the optimal method 
of management seems to depend on anti-HBs levels 
and has not been fully understood. The proper timing 
of booster dose administration is also not generally 
agreed upon (7).
A number of studies in Iran have examined the 
long-term persistence of antibody after hepatitis B 
immunization at birth, and a few of these studies 
have assessed the challenges with administering  a 
booster dose of the vaccine later in life. This study 
was conducted to evaluate the persistence of antibody 
after HBV vaccination and to assess the response to 
a booster dose in 5- to 7-year-old children.
Materials and Methods
This research is a clinical trial performed from 
2004 to 2005 in the Kohgiloyeh and Boyerahmad 
province of Iran. The study’s population included 
children aged 5 to 7 years old who were given a 
full  three-dose  hepatitis  B  vaccine  as  an  infant 
(recombinant  Engerix-  B  Biotec  Havana,  Cuba, 
10µg).  Households  that  were  attended  by  public 
health centers were divided into 100 clusters based on 
the population served: This resulted in 46 urban and 
54 rural clusters. From these clusters, 729 children 
were selected by a multiple-stage sampling method. 
All  parents  were  requested  to  sign  an  informed 
consent form in which they agreed to participate in 
the study. After observing the children’s vaccination 
sheets and interviewing parents for collecting data, 
blood  specimens  (3  ml)  were  obtained  from  the 
children. All specimens were tested by an ELISA 
method (Radim kit- Tahghighgostar Co., Iran) for 
hepatitis B surface antibody (HBsAb) and hepatitis 
B  surface  antigen.  Anti-HBs  concentrations  were 
measured and reported in IU/ml.
The history of hepatitis B infection was noted 
in the parents’ reports. All children with an anti-
HBs  concentration  ≥10  IU/ml  were  considered 
seroprotected  and  excluded  from  further  analysis. 
Subjects with anti-HBs titer < 10 IU/ml received 
a  booster    dose  of  a  recombinant  vaccine   
intramuscularly  in  the  deltoid  muscle.  Blood 
specimens were obtained from these children 4 weeks 
after the administration of the booster dose, and the 
anti-HBs titers were measured again with ELISA. 
The  antibody  titers  after  the  booster  vaccination 
were classified in three groups: 1) non-responders, 
who had anti-HBs levels <10 IU/ml; 2) responders 
with anti-HBs levels ≥10 IU/L and ≤ 100 IU/ml; 
and 3) high responders, who had anti-HBs levels > 
100 IU/ml.
Data analyses were performed using Chi-square, 
independent-samples t-test, paired-samples
t-test, and ANOVA test. P < 0.05 was considered 
significant, and all P values were two sided. 
We assessed the effects of gender, age group, and 
residency on the development of anti-HBs ≥ 10 IU/
ml and on the child’s response after the booster dose 
administration.
The inclusion and exclusion criteria in this study 
were as follows. First, children who had received all 
three doses of the vaccine at infancy were included. 
Of this sample, children were excluded if they had 
a history of HBV infection, positive HBsAg, or a 
history of allergic reactions after receiving hepatitis 
B vaccine (used for the booster dose). These criteria 
were  verified  by  reviewing  children’s  growth  and 
vaccination sheets and by interviewing parents. 
Results
Seven  hundred  and  twenty-nine  children  were 
enrolled in the study. Four hundred and twenty-five 
(58.3%) were males and 304 (41.7%) were female. 
Three hundred forty-eight (47.7%) of the children 
lived in urban areas, and 381 (52.3 %) lived in rural 
areas. One hundred fifty four (21.2%) were 5 years 
old, 257 (35.3%) were 6 years old, and 318 (43.5%) 
were 7 years old.
The  overall  seropositivity  rate  for  anti-HBs 
(≥10I  U/ml)  was  84.4%  (615  children),  and  in 
39.1% (285 children) of these children the antibody 
concentration level was higher than 100 IU/ml. One 
hundred  fourteen  (15.6%)  children  had  anti-HBs 
concentrations  <  10  IU/ml  (non-seroprotective). 
All the children tested negative for HBsAg and had Hepatitis Monthly, Winter 2010; 10(1): 17-21
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no history of HBV infection or clinical evidence of 
infection or disease.
The mean anti-HBs concentration in seropositive 
children was 230.5 ± 308.9 IU/ml, ranging from 
10.6 to 1175. In children without a seroprotective 
titer (no-seroprotective children), the mean antibody 
concentration was 4.97 ± 3.5. The seroprotection rate 
and its relationship with the demographic variables 
such as sex, age, and residential area is shown in Table 
1. The females had a significantly higher mean anti-
HBs titer than males (231.5 ± 320.1 versus 169.3 ± 
273.6, P = 0.006).
The mean anti-HBs titers were 232.5 ± 316.7, 
205.4 ± 305.1, and 169 ± 274.2 in 5-, 6-, and 7-year-
old children, respectively. This differences were not 
statistically significant (P = 0.07).
Table 2 shows the anti-HBs concentration in non-
seroprotective children after receiving the booster 
dose. As shown in Table 2, 89 out of the 114 non-
seroprotective children (78.1%) children responded 
with anti-HBs level ≥ 10 IU/ml after the booster 
dose. The mean anti-HBs concentration in children 
who received the booster dose was 332.1 ± 402 IU/
ml after the booster, which was approximately 67 
times higher than the mean antibody concentration 
before the booster. This difference was statistically 
significant  (P  <  0.05).  There  were  no  significant 
differences in seroprotectivity after the booster dose 
by sex, age group, or area of residence.
Discussion
The  results  of  this  study  indicate  that  the 
majority of the participants (84.4%) who had been 
immunized with recombinant HBV vaccine in their 
first years of life had a protective concentration of 
antibody at 5 to 7 years of age, and 285 (39.1%) 
of  these  children  had  high  anti  body  levels.  Our 
results are similar to those by Salehi et al. (8), who 
reported  that,  6  years  after  vaccination,  81%  of 
Iranian children had protective antibody levels and 
29.2% had high antibody levels. Mahyar reported an 
87.5% seroprotection rate at 6 years old and Behjati 
et al. reported a 69% rate at 7 years old in Iranian 
children after primary vaccination (9, 10). Garcialiop 
et al. reported a 70.6% seroprotection rate in Spanish 
children 6-7 years after vaccination (11). 
Most  studies  have  found  that  there  were  no 
gender differences in the immunological response 
to HBV vaccine (12-14). Similarly, in our study the 
seroprotection  rates  of  girls  and  boys  were  not 
statistically different. However, mean antibody titer 
in girls was significantly higher than the titer in boys; 
this suggests that females are stronger responders. 
This finding is similar to of the results in Gold et al. 
Table  1.    Anti-HBs  concentration  according  to  the  demographic 
characteristics of vaccinated children.  
Anti-HBs 
Concentration
Characteristics
≥10IU/ml  
No. (%)
<10 IU/ml
No. ( %)
Total
No. ( %)
P-value
Male
Sex
Female
356(83.8)       
259(85.2)        
15(16.2)
39(14.8)
425(100)
304(100)
N.S
Urban
Residency
Rural
294(84.5)
321(84.3)
54(15.5)
60((15.7)
348(100)
381(100)
N.S
Five
Age(years)  Six
Seven   
139(90.3)
218(84.8)
258(81.8)
15(9.7)
39(15.2)
60(18.9)
154(100)
257(100)
318(100)
0.04
Table 2. The anti-HBs concentration in non-seroprotective children after 
receiving the booster dose. 
Antibody concentration Number of subjects Percent
<10 IU/ml 25 21.9
≥10 IU/ml and ≤ 100IU/ml 28 24.6
> 100IU/ml 61 53.5
Total 114 100Hepatitis Monthly, Winter 2010; 10(1): 17-21
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and Salehi et al. (8, 15).
In this study the seroprotection rate and mean 
antibody titer were found to decrease with age and 
had  significant  associations  with  the  age  of  the 
children. On the other hand, child’s age negatively 
influenced anti-HBs level. This result corroborates 
findings  from  previous  studies  that  indicate  that 
anti-HBs concentrations decline over time (16-22).
In  our  study  the  majority  of  subjects  (78.1%) 
responded to the booster dose, and more than half 
of them had a high antibody level (>100 IU/ml). 
Other studies on children have shown similar results 
(16, 18, 23).
Immunologic memory was confirmed by the high 
response to the administration of the booster dose 
in the children with an anti-HBs concentration < 10 
IU/ml 5-7 years after the original vaccination series. 
Exposure to the booster antigen in these children 
stimulated the antibody concentration to exceed 100 
IU/ml in more than half of all cases. The statistically 
significant  difference  between  the  mean  antibody 
concentration  before  and  after  the  booster  dose 
shows the vigorous response of the immune system 
to the booster and suggests that the immunologic 
memory is good. 
Similarly,  Gonzales  et  al.’s  follow-up  study  of 
HBV-vaccinated  children  showed  that  the  mean 
antibody  titer  increased  significantly  from  34  to 
2,985 IU/L after a booster in 7-year-old children (P 
< 0. 001) (24).
Evaluating the response to a booster dose of the 
HBV vaccine in subjects with history of vaccination 
at  least  five  years  ago  resulted  in  approving  the 
presence of memory response to the HBs antigen as 
reported in several studies (24-32).
We found no cases of HBsAg reactivity in our 
study subjects, including those who were no longer 
anti-HBs seropositive. The reason for this data may 
be indicative of a lack of contact with HBV or 
induced immunological memory due to their primary 
immunization of this age group. There is no medical 
evidence, however, to show that healthy vaccinated 
children lose their immunity simply because the anti-
HBs level drops below 10 IU/ml (33). In two studies 
carried out on Chinese adolescents 13 to 15 years 
after they had been vaccinated at birth, the results 
showed that fewer than 2% of the adolescents were 
HBsAg seropositive, despite a seroprotectivity rate 
of less than 50% in these studies (34, 35).
In  conclusion,  our  study  on  5-  to  7-year-old 
children who were vaccinated early in life showed that 
an effective seroprotection level persisted in 84.4% 
of subjects. Given this result, that the response to the 
booster dose in 78.1% of children did not result in a 
seroprotective level, and the absence of HBsAg in all 
subjects, we conclude that a routine administration of 
an HBV booster dose is not necessary before 7 years 
of age. Further follow-up studies on older children 
and adolescents are needed to verify the persistence 
of seroprotectivty, immunologic memory, and the 
necessity  of  booster  dose  administration  at  these 
ages. In the present study, about 22% of children 
with  a  non-protective  level  of  anti-HBs  did  not 
respond to the booster dose. More studies are needed 
to evaluate the necessity of extra dose of booster in 
these children.
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